Zimmer Biomet has secured approval from Japan’s Pharmaceutical and Medical Devices Agency (PMDA) for its iTaperloc Complete and iG7 Hip System.
The orthopaedic implants feature Iodine Technology, which is designed to inhibit bacterial adhesion on the implant surface and prevent biofilm formation, thereby addressing periprosthetic joint infections following total joint arthroplasty.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This technology involves applying iodine, a biocompatible element used as an antiseptic, to the implant surface during the production process.
iTaperloc and iG7 integrate the established clinical features of the company’s Taperloc Complete Hip and the G7 Acetabular systems.
Zimmer Biomet chairman, president and CEO Ivan Tornos said: “The earlier-than-expected approval of iTaperloc Complete and iG7 Hip System in Japan further strengthens Zimmer Biomet’s comprehensive portfolio of infection management solutions, which spans prevention, detection, primary and revision products.
“By equipping surgeons with advanced tools to identify and address infection risks throughout the continuum of care, we’re helping drive safer surgical outcomes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This milestone is the latest in our robust new product cycle and underscores our unwavering commitment to delivering first-to-world, transformative innovations that address the most meaningful challenges in musculoskeletal health.”
The technology was developed by Hiroyuki Tsuchiya, emeritus orthopaedic surgery professor at Kanazawa University.
Tsuchiya said: “Iodine Technology represents a significant advancement in orthopaedic implant design.
“By integrating a controlled-release iodine layer through advanced anodization and electrophoresis, we created an implant that inhibits bacterial adhesion and biofilm formation during the postoperative period.”
In April, Zimmer Biomet completed its acquisition of Paragon 28 for approximately $1.2bn, strengthening its foot and ankle orthopaedic capabilities.
Further expanding its capabilities, the company agreed in July to acquire Monogram Technologies, an orthopaedic robotics company.
Valued at approximately $177m, the deal aimed to enhance Zimmer Biomet’s ROSA robotics platform with Monogram’s robotic technologies.
